Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy
Sponsor: University of Pisa
Summary
Metastatic Breast cancer (MBC) patients from ten Italian Divisions of Medical Oncology, with histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1,8 and 15, every 4 weeks, will be enrolled for the present pharmacogenetic study. MBC patients treated with first-line chemotherapy including paclitaxel without bevacizumab will be also enrolled as control group.
Official title: Prospective Evaluation of VEGFR-2 rs11133360/IL-8 rs4073 Genetic Interaction in Metastatic Breast Cancer Patients Treated With Paclitaxel and Bevacizumab vs. Chemotherapy Alone (BEVAPROS)
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
307
Start Date
2014-04
Completion Date
2026-04
Last Updated
2026-05-05
Healthy Volunteers
No
Conditions
Interventions
genetic interaction analysis
VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
Locations (2)
Department of Clinical and Experimental Medicine, University of Pisa
Pisa, I Am Not in the U.S. Or Canada, Italy
Azienda USL 5 of Pisa
Pontedera, Pisa, Italy